(S)-(-)-N-[[3-[4-(trimethylstannyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide | 188975-87-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (S)-(-)-N-[[3-[4-(trimethylstannyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
• 英文别名: (5S)-acetamidomethyl-3-(4-trimethyltinphenyl)oxazolidin-2-one；N-[5(S)-3-[4-(trimethylstannyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide；N-({(5S)-2-Oxo-3-[4-(trimethylstannyl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide；N-[[(5S)-2-oxo-3-(4-trimethylstannylphenyl)-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 188975-87-3
• 化学式: C₁₅H₂₂N₂O₃Sn
• 分子量: 397.061
• InChiKey: CLFMXZIMJYLKAW-HZAYLZKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.69
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-(-)-N-[[3-[4-(trimethylstannyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 生成 (S)-(-)-4-[4-[5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinecarboxylic acid 1,1-dimethylethyl ester
  参考文献：
  名称：

  Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings

  摘要：

  该化合物的公式为（I）：其中X是NR.sub.1，S（O）.sub.g或O；R.sub.1是H，C.sub.1-6烷基，可选地取代一个或多个OH，CN或卤素，或R.sub.1是-（CH.sub.2）.sub.h-芳基，-COR.sub.1-1，-COOR.sub.1-2，-CO-（CH.sub.2）.sub.h-COR.sub.1-1，C.sub.1-6烷基磺酰基，-SO.sub.2-（CH.sub.2）.sub.h-芳基，或-（CO）.sub.i-Het；R.sub.2是H，C.sub.1-6烷基，-（CH.sub.2）.sub.h-芳基或卤素；R.sub.3和R.sub.4相同或不同，是H或卤素；R.sub.5是H，C.sub.1-12烷基，可选地取代一个或多个卤素，C.sub.3-12环烷基，C.sub.1-6烷氧基。这些化合物是有用的抗菌剂。

  公开号：

  US05968962A1
• 作为产物：
  描述：

  六甲基二锡 、 (S)-N-<<3-(4-iodophenyl)-2-oxo-5-oxazolidinyl>methyl>acetamide 在 Pd(PPh₃)Cl₂ 作用下， 以 1,4-二氧六环 为溶剂， 以59%的产率得到(S)-(-)-N-[[3-[4-(trimethylstannyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
  参考文献：
  名称：

  Antibiotic oxazolidinone derivatives

  摘要：

  这项发明涉及一种式(I)的化合物：##STR1##其中R.sup.1 -R.sup.6，A，B和D具有规范中定义的任何值，或其药学上可接受的盐，以及包括这种化合物或盐的药物组合物，以及通过给予这种化合物或盐来治疗细菌感染的方法。

  公开号：

  US05981528A1

文献信息

• Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US20030125367A1

  公开（公告）日：2003-07-03

  Oxazolidinones having a bicyclic[3.1.0] hexane containing moiety, which are effective against aerobic and anerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides spp., Clostridia spp. species, as well as acid-fast organisms such as Mycobacterium tuberculosis and other mycobacterial species. The compounds are represented by structural formula I: 1 its enantiomer, diastereomer, or pharmaceutically acceptable salt or ester thereof, and wherein the variables R 1 , R 2 , R 3 , R 4 , R 4a , A, Ar, HAr, n, r, and s are as defined herein.

  含有含有双环[3.1.0]己烷基团的噁唑烷酮，对需氧菌和厌氧病原体具有有效作用，如多耐药葡萄球菌、链球菌和肠球菌、Bacteroides属、Clostridia属物种，以及酸快细菌如结核分枝杆菌和其他分枝杆菌物种。该化合物由结构式I表示：其对映体、二对映体或其药用可接受的盐或酯，其中变量R1、R2、R3、R4、R4a、A、Ar、HAr、n、r和s的定义如本文所述。
• Oxazolidinone and/or isoxazoline as antibacterial agents
  申请人：Gravestock Barry Michael

  公开号：US20050107435A1

  公开（公告）日：2005-05-19

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in (I) wherein C is for example wherein A and B are independently selected from R 2 a to R 3 b are independently selected from hydrogen and fluorine; R 1 a and R 1 b are independently selected from, for example, hydroxy, —NHC(═W)R 4 , wherein W is O or S; R 4 is, for example, hydrogen, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsaturated heterocyclic ring; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  公式（I）的化合物，或其药学上可接受的盐，或其体内可水解的酯，以及公式（I）中C代表的化合物，例如其中A和B分别独立地选自R2a至R3b，R1a和R1b独立地选自例如羟基，—NHC（═W）R4，其中W为O或S；R4例如为氢，氨基，（1-4C）烷基；HET-1例如为C-连接的5-成员杂芳环；HET-2例如为N-连接的5-成员，完全或部分不饱和的杂环；可用作抗菌剂；并描述了它们的制造工艺和含有它们的药物组合物。
• Oxazolidinone And/Or Isoxazoline As Antibacterial Agents
  申请人：Gravestock Michael Barry

  公开号：US20100137243A1

  公开（公告）日：2010-06-03

  Compounds of Formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in Formula (I) wherein C is for example (D), (E), (F); wherein A and B are independently selected from (i) and (ii); R 2 a to R 3 b are independently selected from hydrogen and fluorine; R 1 a and R 1 b are independently selected from, for example, hydroxy, —NHC(═W)R 4 , (a) and (b); wherein W is O or S; R 4 is, for example, hydrogen, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsaturated heterocyclic ring; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  式(I)的化合物，或其药学上可接受的盐，或其体内可水解的酯，以及式(I)中C代表(D)、(E)、(F)等的化合物；其中A和B分别选自(i)和(ii)；R2a和R3b独立选择自氢和氟；R1a和R1b独立选择自羟基、—NHC(═W)R4、(a)和(b)等；其中W为O或S；R4例如为氢、氨基、(1-4C)烷基；HET-1例如为C-连接的5元杂环芳基环；HET-2例如为N-连接的5元，完全或部分不饱和的杂环环；这些化合物对抗菌有用；并描述了它们的制造过程和含有它们的制药组合物。
• Antibiotic oxazolidinone derivatives
  申请人：Zeneca Ltd.

  公开号：US06365751B1

  公开（公告）日：2002-04-02

  The invention concerns a compound of the formula (I): wherein, for example: R1 is of the formula —NHC(═O)Rb wherein Rb is, for example, (1-4C)alkyl; R2 and R3 are hydrogen or fluoro; R2 and R3 are hydrogen or fluoro; D is O; R4 and R5 are hydrogen, (1-4C)alkyl or AR-oxymethyl; AR is phenyl or phenyl(1-4C)alkyl; R6 is hydrogen; >A—B— is of the formula >C═C(Ra)—, >CHCHRa—, or >C(OH)CHRa— (> represents two single bonds) wherein Ra is hydrogen or (1-4C)alkyl; and pharmaceutically-acceptable salts thereof; processes for their preparation; pharmaceutical compositions containing them and their use as antibacterial agents.

  本发明涉及如下公式(I)的化合物：其中，例如：R1是如下公式的形式—NHC(═O)Rb，其中Rb例如为(1-4C)烷基；R2和R3是氢或氟；D是氧；R4和R5是氢，(1-4C)烷基或AR-甲氧基甲基；AR是苯基或苯基(1-4C)烷基；R6是氢；>A—B—是如下公式的形式>C═C(Ra)—, >CHCHR_a—, 或 >C(OH)CHR_a—（>代表两个单键），其中Ra是氢或(1-4C)烷基；以及它们的药用可接受盐；它们的制备过程；含有它们的药物组合物以及它们作为抗菌剂的用途。
• Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings
  申请人：Pharmacia & Upjohn Company

  公开号：US05968962A1

  公开（公告）日：1999-10-19

  A compound of the formula (I): ##STR1## or pharmaceutical acceptable salts thereof wherein X is NR.sub.1, S(O).sub.g, or O; R.sub.1 is H, C.sub.1-6 alkyl optionally substituted with one or more OH, CN, or halo, or R.sub.1 is --(CH.sub.2).sub.h -- aryl, --COR.sub.1--1, --COOR.sub.1-2, --CO--(CH.sub.2).sub.h --COR.sub.1--1, C.sub.1-6 alkyl sulfonyl, --SO.sub.2 --(CH.sub.2).sub.h --aryl, or --(CO).sub.i --Het; R.sub.2 is H, C.sub.1-6 alkyl, --(CH.sub.2).sub.h --aryl, or halo; R.sub.3 and R.sub.4 are the same or different and are H or halo; R.sub.5 is H, C.sub.1-12 alkyl optionally substituted with one or more halo, C.sub.3-12 cycloalkyl, C.sub.1-6 alkoxy. The compounds are useful antimicrobial agents.

  该化合物的公式为（I）：其中X是NR.sub.1，S（O）.sub.g或O；R.sub.1是H，C.sub.1-6烷基，可选地取代一个或多个OH，CN或卤素，或R.sub.1是-（CH.sub.2）.sub.h-芳基，-COR.sub.1-1，-COOR.sub.1-2，-CO-（CH.sub.2）.sub.h-COR.sub.1-1，C.sub.1-6烷基磺酰基，-SO.sub.2-（CH.sub.2）.sub.h-芳基，或-（CO）.sub.i-Het；R.sub.2是H，C.sub.1-6烷基，-（CH.sub.2）.sub.h-芳基或卤素；R.sub.3和R.sub.4相同或不同，是H或卤素；R.sub.5是H，C.sub.1-12烷基，可选地取代一个或多个卤素，C.sub.3-12环烷基，C.sub.1-6烷氧基。这些化合物是有用的抗菌剂。